In Brief
Refine Search
Biotechnology
Japanese drugmaker Eisai today that the humanized antisoluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been launched in South Korea. 28 November 2024
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
A pharma company created last year with the merger of 10 privately-held biotech companies has cut a second drug program of the summer. 11 August 2022
Biotechnology
Shares of US biopharma company VYNE Therapeutics closed down 22.9% at $0.31 yesterday, having plunged as much as 35%, after it revealed results from the Phase IIa segment of a Phase Ib/IIa clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD) that failed to hit its goal. 11 August 2022
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello saw its shares rise 8.7% to 153.80 kroner by mid-morning today, as it reported strong financial results for the second quarter of 2022. 11 August 2022
Generics
Indian drugmaker Strides Pharma Science today announced that its formulation facility at Singapore underwent a US Food and Drug Administration (FDA) inspection that ended on August 8, 2022. 11 August 2022
Biotechnology
Positive top-line results from a Phase III trial of the first CAR T-cell therapy in multiple myeloma have been presented by developers Bristol Myers Squibb and 2seventy bio. 10 August 2022
Biotechnology
Gemini Therapeutics and privately-held clinical-stage Disc Medicine today announced a merger agreement to create a NASDAQ-listed, clinical stage biopharma focused on advancing Disc’s pipeline of hematology programs. 10 August 2022
Biotechnology
Boston, USA-based engineered regulatory T cells (Tregs) company GentiBio has entered into a collaboration with US pharma major Bristol Myers Squibb to develop new engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD). 10 August 2022
Biotechnology
Efforts on the part of Swiss pharma giant Roche to take on AstraZeneca in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) advanced a step this week. 10 August 2022
Pharmaceutical
Japanese pharma major Shionogi today announced that ensitrelvir fumaric acid (S-217622), Shionogi’s orally administered antiviral drug for COVID-19 (caused by infection with the novel coronavirus [SARS-CoV-2]), shows high in vitro antiviral activity against the Omicron subvariant (BA.2.75), with antiviral potency in pre-clinical testing similar to its potency against other existing variants. 10 August 2022
Biotechnology
Belgian cell therapy company Bone Therapeutics is to acquire a majority stake in Medsenic, a privately-held French biopharma specializing in the development of optimized formulations of arsenic salts and their application in inflammatory conditions and other indications. 10 August 2022
Biotechnology
The European Commission (EC) and US biotech Moderna have reached an agreement to address the demand for COVID-19 vaccines for the late summer and winter period. 10 August 2022
Pharmaceutical
US Health and Human Services (HHS) Secretary Xavier Becerra yesterday took action that will allow the US Food and Drug Administration (FDA) Commissioner to grant emergency use authorizations (EUA) for monkeypox vaccines, following the August 4 declaration of a public health emergency for monkeypox. 10 August 2022
Biotechnology
US biotech Novavax, which is dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, has announced its financial results for the second quarter ended June 30, 2022. 10 August 2022
Biotechnology
California, USA-based Appia Bio, a pre-clinical-stage biotechnology company today announced that Jason Damiano has been appointed as its chief scientific officer. 10 August 2022
Pharmaceutical
Catalent announced that it has reached an agreement to acquire Metrics Contract Services (Metrics), a full-service specialty Contract Development and Manufacturing Organization (CDMO) with a facility in Greenville, North Carolina, USA. 10 August 2022
Pharmaceutical
Miami-based Veru has presented Phase III results on sabizabulin in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) at the International Conference on Emerging Infectious Diseases. 9 August 2022
Pharmaceutical
Cerevance, a British clinical-stage biotech working on new medicines for brain disorders, has inked a deal with Merck & Co, focused on Alzheimer’s disease. 9 August 2022
Pharmaceutical
SIGA Technologies’ shares were up 6.8% at $23.67 mid-morning today, as it announced the exercise of procurement options under its 19C contract with the US Department of Health and Human Services for the delivery to the US government of intravenous (IV) formulation of TPOXX treatment courses valued at around $26 million. 9 August 2022
Biotechnology
Late-breaking post-hoc exploratory results from the POSEIDON Phase III trial suggest a trend for improved overall survival (OS) with a limited course of five cycles of tremelimumab added to AstraZeneca’s Imfinzi (durvalumab) plus platinum chemotherapy, in the first-line treatment of patients with STK11, KEAP1 or KRAS-mutated Stage IV (metastatic) non-small cell lung cancer (mNSCLC). 9 August 2022
Pharmaceutical
A trial testing the use of cyclosporine in the treatment of COVID-19 has been stopped after independent data monitors decided it would likely fail. 9 August 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze